Librium

Chlordiazepoxide is listed by exact name in Schedule IV under the Controlled Substances Act at 21 C.F.R. § 1308.14(c)(10), effective July 2, 1975. The listing covers any quantity of chlordiazepoxide, including its salts, isomers, and salts of isomers where chemically possible, unless specifically excepted or listed in another schedule. Federal law controls possession, manufacture, distribution, dispensing, and possession with intent to manufacture, distribute, or dispense; possession obtained directly or pursuant to a valid prescription or order, and other authorized possession, is excepted. Chlordiazepoxide-and-clidinium combination products listed in the DEA Table of Exempted Prescription Products are exempt from specified Controlled Substances Act requirements under 21 C.F.R. § 1308.32.

Chlordiazepoxide is expressly listed among benzodiazepines in Schedule IV, item 18(4), of the Controlled Drugs and Substances Act, effective 14 May 1997. The Act prohibits trafficking, possession for trafficking, unauthorized import or export, possession for export, unauthorized production, and obtaining chlordiazepoxide from a practitioner without the disclosure required by subsection 4(2). The ordinary-possession prohibition in subsection 4(1) applies only to substances in Schedules I, II, and III, not to chlordiazepoxide as a Schedule IV substance. The Benzodiazepines and Other Targeted Substances Regulations also list chlordiazepoxide as a Class 1 targeted substance and generally permit a pharmacist to provide it to an individual pursuant to a prescription.

Chlordiazepoxide is named as a psychotropic substance in the First Schedule to the Health Products (Therapeutic Products) Regulations 2016, including preparations containing it. Two currently registered products combining chlordiazepoxide 5 mg, or chlordiazepoxide hydrochloride 5 mg, with clidinium bromide 2.5 mg are classified as prescription-only medicines, without an exemption for supply without a prescription. Regulation 11 restricts their retail supply to specified pharmacy, healthcare-service, practitioner, and scheduled-exemption channels.